Steven E. Benner, MD, Senior Vice President and Global Therapeutic Head for Oncology at Astellas Oncology gives an overview of an abstract presented by Jessica K. Altman, MD of Feinberg School of Medicine at Northwestern University, which focuses on gilteritinib for FLT3 mutation-positive relapsed/refractory acute myeloid leukemia.
Abstract 7003: Deep molecular response to gilteritinib to improve survival in FLT3 mutation-positive relapsed/refractory acute myeloid leukemia
Advertisement